...
首页> 外文期刊>Peptides: An International Journal >Human adrenomedullin and its binding protein ameliorate sepsis-induced organ injury and mortality in jaundiced rats.
【24h】

Human adrenomedullin and its binding protein ameliorate sepsis-induced organ injury and mortality in jaundiced rats.

机译:人肾上腺髓质素及其结合蛋白改善了败血症诱发的黄疸大鼠器官损伤和死亡率。

获取原文
获取原文并翻译 | 示例
           

摘要

Sepsis is a serious complication for patients with obstructive jaundice. Although administration of adrenomedullin (AM) in combination with its binding protein (AMBP-1) is protective after injury, it remains unknown whether AM/AMBP-1 ameliorates sepsis-induced organ injury and mortality in the setting of biliary obstruction. The aim of this study is, therefore, to test the efficacy of human AM/AMBP-1 in a rat model of obstructive jaundice and polymicrobial sepsis. To study this, obstructive jaundice was induced in male adult rats (275-325g) by common bile duct ligation (BDL). One week after BDL, the rats were subjected to sepsis by cecal ligation and puncture (CLP). Plasma levels of AM and AMBP-1 were measured at 20h after CLP. In additional groups of BDL+CLP rats, human AM/AMBP-1 (24/80microg/kg body weight (BW)) or vehicle (i.e., human albumin) was administered intravenously at 5h after CLP. Blood and tissue samples were collected at 20h after CLP for various measurements. To determine the long-term effect of human AM/AMBP-1 after BDL+CLP, the gangrenous cecum was removed at 20h after CLP and 7-day survival was recorded. Our results showed that plasma levels of AM were significantly increased while AMBP-1 levels were markedly decreased after BDL+CLP (n=8, P<0.05). Administration of human AM/AMBP-1 attenuated tissue injury and inflammatory responses after BDL+CLP. Moreover, human AM/AMBP-1 significantly increased the survival rate from 21% (n=14) to 53% (n=15). Thus, human AM/AMBP-1 ameliorates sepsis-induced organ injury and mortality in jaundiced rats. Human AM/AMBP-1 can be further developed as a novel treatment for sepsis in jaundiced patients.
机译:脓毒症是梗阻性黄疸患者的严重并发症。尽管肾上腺髓质素(AM)及其结合蛋白(AMBP-1)的结合在损伤后具有保护作用,但尚不清楚AM / AMBP-1是否能改善败血症引起的器官损伤和胆道梗阻的死亡率。因此,本研究的目的是测试人AM / AMBP-1在阻塞性黄疸和微生物败血症大鼠模型中的功效。为了研究这一点,通过胆总管结扎术(BDL)在成年雄性大鼠(275-325g)中诱发了阻塞性黄疸。 BDL后1周,通过盲肠结扎和穿刺(CLP)使大鼠败血症。 CLP后20小时测量血浆AM和AMBP-1。在另外的BDL + CLP大鼠组中,在CLP后5小时静脉内施用人AM / AMBP-1(24 / 80microg / kg体重(BW))或媒介物(即人白蛋白)。 CLP后20小时收集血液和组织样本进行各种测量。为了确定BDL + CLP后人AM / AMBP-1的长期作用,在CLP后20h去除坏疽盲肠并记录7天生存期。我们的结果显示,BDL + CLP后,血浆AM的血浆水平显着升高,而AMBP-1的水平则显着降低(n = 8,P <0.05)。 BDL + CLP后给予人AM / AMBP-1可减轻组织损伤和炎症反应。此外,人类AM / AMBP-1的生存率从21%(n = 14)显着提高到53%(n = 15)。因此,人AM / AMBP-1改善了黄疸大鼠败血症诱导的器官损伤和死亡率。人AM / AMBP-1可以进一步开发为黄疸患者败血症的新型治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号